ITMR - Itamar Medical Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
22.74
-0.36 (-1.56%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close23.10
Open23.69
Bid22.74 x 1200
Ask23.85 x 1300
Day's Range22.55 - 23.69
52 Week Range7.66 - 23.69
Volume6,655
Avg. Volume17,625
Market Cap322.694M
Beta (5Y Monthly)0.58
PE Ratio (TTM)N/A
EPS (TTM)-0.72
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.31
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Hedge Funds Have Never Been This Bullish On Itamar Medical Ltd. (ITMR)
      Insider Monkey

      Hedge Funds Have Never Been This Bullish On Itamar Medical Ltd. (ITMR)

      In this article you are going to find out whether hedge funds think Itamar Medical Ltd. (NASDAQ:ITMR) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

    • Itamar Medical Ltd. Sponsored ADR (ITMR) Upgraded to Buy: Here's What You Should Know
      Zacks

      Itamar Medical Ltd. Sponsored ADR (ITMR) Upgraded to Buy: Here's What You Should Know

      Itamar Medical Ltd. Sponsored ADR (ITMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

    • Itamar Medical's Shares March Higher, Can It Continue?
      Zacks

      Itamar Medical's Shares March Higher, Can It Continue?

      As of late, it has definitely been a great time to be an investor in Itamar Medical.

    • GlobeNewswire

      Itamar Medical Reports First Quarter 2020 Financial Results

      - First Quarter 2020 Revenues Increase 38% to $8.4 Million - - WatchPAT™ Revenues Increase 41% to $8.2 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm.

    • GlobeNewswire

      Itamar Medical Announces Date Change for First Quarter Financial Results and Conference Call to May 27, 2020

      CAESAREA, Israel, May 19, 2020 -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive.

    • GlobeNewswire

      Itamar Medical to Report First Quarter Financial Results and Host Conference Call on Thursday, May 28, 2020

      Itamar Medical Ltd. (ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, announced today that it will report its unaudited financial results for the first quarter 2020 before the U.S. market opens on Thursday, May 28, 2020. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update. The call will be hosted by Gilad Glick, President and CEO, and Shy Basson, CFO & US COO.

    • GlobeNewswire

      Itamar Medical Receives CE Mark Approval for its WatchPAT™ ONE, the First Fully Disposable Home Sleep Apnea Test

      Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical solutions to aid in the diagnosis of respiratory sleep disorders, today announced receipt of CE mark approval for the Company’s WatchPAT™ ONE. The CE mark allows Itamar to expand commercialization of the latest innovation of its WatchPAT technology and the first fully disposable Home Sleep Apnea Test (HSAT), throughout Europe and other CE Mark geographies.

    • GlobeNewswire

      Itamar™ Medical Funds Clinical Study to Evaluate Potential Impact of CPAP Therapy to Patients with COVID-19 

      Itamar Medical Ltd. (ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices, solutions and a digital health platform to aid in the diagnosis of respiratory sleep disorders, today announced the initiation of a funded trial that will evaluate the use of CPAP to manage patients with confirmed or suspected COVID-19. The study is a prospective, single-center, parallel group, open-label, randomized clinical trial to assess the efficacy of CPAP in 200 COVID-19 confirmed or suspected patients within the Mount Sinai Health System with respiratory symptoms who do not require hospital admission and are discharged home from the emergency room.

    • GlobeNewswire

      Itamar™ Medical Announces First Quarter 2020 Preliminary Revenue Increase of Approximately 40%

      Itamar Medical Ltd. (ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices, solutions and a digital health platform to aid in the diagnosis of respiratory sleep disorders, today provided an update on actions the Company is taking in response to the COVID-19 pandemic. The Company is also providing a preliminary range for its first quarter 2020 revenues and is withdrawing its full year 2020 financial guidance due to current global market uncertainties. At March 31, 2020, Itamar Medical had an accumulated backlog of the recently introduced WatchPAT ONE orders of approximately $550,000, mostly created in the last three weeks of March 2020.

    • GlobeNewswire

      Itamar™ Medical and BetterNight to Join Forces Offering Referred Patients Home Based Virtual-Care Sleep Solution for the Diagnosis and Treatment of Sleep Apnea

      Itamar Medical Ltd. (ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices, solutions and a digital health platform to aid in the diagnosis of respiratory sleep disorders, today announced that it has entered into an agreement with Sleep Data Diagnostics and its virtual-care platform BetterNight and Sleep Data Holdings, a leading provider of home-based positive airway pressure (PAP) services. This agreement is designed to radically simplify the process by which both sleep and non-sleep referring physicians, such as cardiologists, can refer their patients for sleep apnea testing with WatchPAT™ through Itamar Medical and BetterNight’s platforms providing a full care pathway that includes testing, medical consultation, continuous positive airway pressure (CPAP) therapy, billing and reimbursement channels.

    • GlobeNewswire

      Itamar™ Medical Implements Broad Range of Actions in Response to COVID-19 Pandemic

      Itamar Medical Ltd. (Nasdaq:  ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today released the following letter from its President and CEO, Gilad Glick. Itamar Medical shares its heartfelt empathy with the communities impacted worldwide by the Coronavirus (COVID-19). Prior to the outbreak of COVID-19, as part of Itamar Medical’s regular business continuity plan, our inventory included a material safety stock, which has allowed us to meet all commitments to date despite early supply chain disruptions in China.

    • GlobeNewswire

      Itamar™ Medical Reports Record Fourth Quarter and Full Year 2019 Revenues

      - Record Fourth Quarter 2019 Revenues Increase 48% to $9.8 Million -  - Reaffirms Full Year 2020 Revenue Guidance of between $39.5 Million and $42.0 Million - - Company to.

    • GlobeNewswire

      Itamar™ Medical and Clalit Research Institute Establish Research Collaboration to Explore WatchPAT Signals’ Ability to Predict Health Outcomes Using Existing Big Data and Artificial Intelligence

      Itamar Medical Ltd. (Nasdaq:  ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced that it has entered into a research collaboration agreement with Clalit Research Institute (CRI), a subsidiary of Clalit Health Services (CHS), Israel’s largest state-mandated health service organization. Under the agreement, Itamar and CRI will collaborate to conduct a study designed to determine if data from the WatchPAT signal can help predict cardiovascular health outcomes. The study will use artificial intelligence tools to compare predictive models for different outcomes, such as cardiovascular disease, atrial fibrillation, congestive heart failure and other outcomes.

    • GlobeNewswire

      Itamar™ Medical to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 3, 2020

      Itamar Medical Ltd. (ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, announced today that it will report its unaudited financial results for the fourth quarter and full year 2019 before the U.S. market opens on Tuesday, March 3, 2020. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update. The call will be hosted by Gilad Glick, President and CEO, and Shy Basson, CFO & US COO.

    • GlobeNewswire

      Itamar™ Medical Announces Publication of COMPASS Study Validating First Scoring Guidelines for WatchPAT™ Device in Diagnosing Sleep Apnea

      Itamar Medical Ltd. (ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced publication of results of the COMPASS study validating scoring guidelines that better enable physicians and respiratory technologists to review, verify and interpret WatchPAT automated scoring. The study also found that the use of those guidelines is reliable and improves agreement between WatchPAT and gold standard polysomnography (PSG)-derived sleep and breathing indices across age and gender subgroups.

    • GlobeNewswire

      Itamar™ Medical Announces Closing of Upsized Public Offering of American Depositary Shares and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs

      Itamar Medical Ltd. (ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the closing of its upsized public offering of 2,927,267 American Depositary Shares (“ADSs”), which includes the full exercise of the underwriters’ option to purchase 381,817 additional ADSs, at a public offering price of $13.75 per ADS, for total gross proceeds of approximately $40.25 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Itamar Medical. Each ADS represents 30 ordinary shares of Itamar Medical. All ADSs are being offered by Itamar Medical.

    • GlobeNewswire

      Itamar™ Medical Announces Upsizing and Pricing of Public Offering of American Depositary Shares

      Itamar Medical Ltd. (ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the upsizing and pricing of its public offering of 2,545,450 American Depositary Shares (“ADSs”) at a public offering price of $13.75 per ADS, for total gross proceeds of approximately $35.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Itamar Medical. Each ADS represents 30 ordinary shares of Itamar Medical. All of the ADSs are being offered by Itamar Medical.

    • GlobeNewswire

      Itamar™ Medical Announces Proposed $30 Million Offering of American Depositary Shares

      Itamar Medical Ltd. (ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the commencement of a proposed $30 million public offering of American Depositary Shares (“ADSs”). Each ADS represents 30 ordinary shares of Itamar Medical. All of the ADSs to be sold in the offering will be offered by Itamar Medical.

    • GlobeNewswire

      Itamar™ Medical Announces Preliminary Revenue for Fourth Quarter and Full Year 2019 and Revenue Guidance for Full Year 2020

      Itamar Medical Ltd. (ITMR) (ITMR), a company that develops, manufactures and markets non-invasive diagnostic prescription medical devices to aid in the diagnosis of respiratory sleep disorders with a focus on the Core Sleep, Cardiology and Digital Health markets, today reported preliminary unaudited revenue results for the fourth quarter and full year ended December 31, 2019 and announced revenue guidance for the full year 2020. Total revenue for the fourth quarter of 2019 is expected to be $9.6 to $9.8 million, an increase of 46% to 49% compared to $6.6 million in the same quarter in 2018.

    • GlobeNewswire

      Itamar Medical Selected to Participate in the Prestigious Weizmann Institute Project 10K

      Itamar Medical Ltd. (ITMR) (ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today announced that its WatchPAT has been selected for inclusion in the Weizmann Institute’s Project 10K. One of the largest projects of its kind, the 10K Project is a longitudinal study designed to collect lifestyle and clinical data from 10,000 individuals over ten years and aims to use state-of-the-art artificial intelligence technologies to analyze the data in order to generate personalized predictions for disease risk factors.

    • GlobeNewswire

      Itamar™ Medical and SoClean® Announce Collaboration to Offer WatchPAT™ ONE and other Digital Health Services Through Direct-to-Consumer Channels

      Itamar Medical Ltd. (ITMR) (ITMR), ( “Itamar Medical”) a company that develops, manufactures and markets non-invasive ambulatory diagnostic medical devices for sleep apnea and offers Total Sleep Solution using a cloud based digital health platform, and SoClean Inc., a company that develops, manufactures and markets sleep equipment sanitizers through direct-to-consumer (DTC) channels to the sleep apnea market, today announced a collaboration agreement between their respective wholly owned subsidiaries to make Itamar Medical’s WatchPAT ONE home sleep apnea test and Digital Health Services available to consumers. The collaboration is designed to overcome the barriers to sleep apnea testing and therapy solutions by enabling consumers to purchase remote sleep consultations and home-based sleep test using the WatchPAT ONE in the comfort of their own homes.

    • GlobeNewswire

      Itamar™ Medical Reports Record Third Quarter 2019 Revenues

      - Third Quarter Revenues Increase 33% to $8.1 Million - - WatchPAT™ Revenues Increase 32% in the Third Quarter to $7.6 Million - - Company to Host Conference Call Today at.

    • GlobeNewswire

      Itamar Medical to Present at the Piper Jaffray 31st Annual Healthcare Conference on December 4, 2019

      Itamar Medical Ltd. (ITMR) (ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, announced today that Gilad Glick, President and Chief Executive Officer of Itamar Medical, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference in New York, NY, on Wednesday, December 4, 2019 at 4:30 PM ET. A live and archived webcast of the presentation will be available on the investor section of the Company’s website at: www.itamar-medical.com.

    • GlobeNewswire

      Itamar™ Medical to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 26, 2019

      Itamar Medical Ltd. (ITMR) (ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, announced today that it will report its unaudited financial results for the third quarter of 2019 before the U.S. market opens on Tuesday, November 26, 2019. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update.